Xenon Announces Appointment of EVP, Research & Development

Xenon Announces Appointment of EVP, Research & Development
 
VANCOUVER, May 17 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce today that it has appointed Tarek S. Mansour as Executive Vice President, Research and Development.

"We are delighted to welcome Tarek to the Xenon team," commented Simon Pimstone, Xenon's President and CEO. "Tarek is a world-class R&D executive whose experience in discovering products, a number of which are now on the market, will further enhance Xenon's capabilities.  Tarek has had the unique experience of holding senior leadership positions within both biotech and more traditional pharmaceutical companies.  His successful careers at Biochem Pharma and Wyeth Pharmaceuticals (now Pfizer) have armed Tarek with best-in-class drug discovery and development practice and we are confident that Tarek will make a major contribution to Xenon's future innovative R&D efforts."

Dr. Mansour has spent nearly 25 years in the life sciences industry with positions at Biochem Pharma, and Wyeth Pharmaceuticals (now Pfizer). His most recent position at Wyeth Research was as VP, Chemical Sciences Head over multiple research sites. Dr. Mansour received his PhD in Chemistry from the University of Missouri - Columbia.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  Xenon has multiple products in phase 1 and 2 clinical development.  For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


SOURCE Xenon Pharmaceuticals Inc.

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.